Neurological Headache Centre, S. Andrea Hospital, La Sapienza University, Rome, Italy.
Neurol Sci. 2011 Apr;32(2):269-73. doi: 10.1007/s10072-010-0443-x. Epub 2010 Nov 11.
Primary headaches are underdiagnosed and undertreated in patients with multiple sclerosis (MS). The aim of our study was to investigate the possibility of using the ID migraine™ (ID-M) questionnaire to make a first-line diagnosis of migraine in subjects affected by MS. We consecutively recruited 144 patients regularly attending the MS Centre of S. Andrea Hospital in Rome. Results from ID-M were matched with diagnoses of a blind neurologist. According to the ICHD-II criteria, 77 (53.5%) patients were diagnosed as suffering from migraine. ID-M showed high sensitivity (91%) and specificity (94%) in identifying patients with migraine. ID-M was also able to discriminate patients affected by headache following interferon beta therapy, having only the 10% out of these patients a positive ID-M. The use of the ID-M as a screening test is warranted not only in the epidemiological research, but also to ensure a better clinical management of patients with MS.
原发性头痛在多发性硬化症（MS）患者中被诊断不足且治疗不足。我们研究的目的是探讨使用 ID 偏头痛™（ID-M）问卷对受 MS 影响的患者进行偏头痛一线诊断的可能性。我们连续招募了 144 名定期在罗马 S. Andrea 医院 MS 中心就诊的患者。ID-M 的结果与盲法神经病学家的诊断相匹配。根据 ICHD-II 标准，77 名（53.5%）患者被诊断为偏头痛。ID-M 在识别偏头痛患者方面具有很高的敏感性（91%）和特异性（94%）。ID-M 还能够区分因干扰素β治疗而出现头痛的患者，其中只有 10%的患者 ID-M 呈阳性。ID-M 不仅在流行病学研究中，而且在确保更好地管理 MS 患者方面，都需要作为一种筛查测试。
